Home » Posts tagged with » Sweden
NeuroVive completes enrollment in KL1333 clinical trial for mitochondrial disease

NeuroVive completes enrollment in KL1333 clinical trial for mitochondrial disease

KL1333 clinical trial : Swedish biotech company NeuroVive Pharmaceutical has wrapped up recruitment of healthy volunteers in the second part of its ongoing phase Ia/b clinical trial for its drug candidate drug KL1333 for the chronic oral treatment of primary mitochondrial disease. According to NeuroVive Pharmaceutical, the first part of the clinical study assessed the […]

Recipharm to acquire British CDMO Consort Medical for £505m

Recipharm acquisition of Consort Medical : Swedish pharma group Recipharm has agreed to acquire Consort Medical, a British contract development and manufacturing organization (CDMO) for £505 million, as per the latest pharma acquisition news. The transaction is said to help Recipharm become a major inhalation company and places it among the top five CDMO players […]

Continue reading …
Sobi to acquire US pharma company Dova Pharmaceuticals in $915m deal

Sobi acquisition of Dova Pharmaceuticals : Swedish Orphan Biovitrum (Sobi) has signed a deal worth up to $915 million to acquire Dova Pharmaceuticals, a US pharma company, in a move to become a major player in hematology and orphan diseases and also for expanding its footprint in the US. Shareholders of Dova Pharmaceuticals will be […]

Continue reading …
Cyxone achieves safety, tolerability goals in T20K MS clinical trial

T20K MS clinical trial : Swedish biotech company Cyxone said that a phase 1 clinical trial for its drug candidate T20K for multiple sclerosis (MS) has confirmed its safety and tolerability in humans. Cyxone said that there were no serious adverse events in the early-stage infusion study. As the next step in its development program, […]

Continue reading …
Calliditas initiates NEFIGARD trial to study Nefecon in Berger’s disease

Nefecon phase 3 trial : Calliditas Therapeutics has initiated a phase 3 clinical trial called NEFIGARD to evaluate its lead candidate Nefecon for the treatment of IgA nephropathy (IgAN), which is also known as Berger’s disease. Phase 3 NEFIGARD trial of Nefecon The Swedish pharma company has enrolled the first patient for the late-stage NEFIGARD […]

Continue reading …
Sickle cell disease drug developer Modus Therapeutics raises $16m in new funding

Modus Therapeutics, a Swedish biotech company focused on developing sickle cell disease drugs, has raised SEK 140 million ($15.76 million) in a funding round led by new investor HealthCap, a European venture capital firm. HealthCap, which makes investments in breakthrough therapies of diseases with highly unmet medical needs, had injected SEK 60 million ($6.75 million) […]

Continue reading …